

Medical Policies



Policy Y-5046

Number:

Policy Name: Intensity-Modulated Radiotherapy of the Breast and Lung

Policy Type: Medical Policy Therapy

Subtype:

Effective 09-15-2025 End Date: 11-02-2025

Date:

Description

For certain stages of many cancers, including breast and lung, randomized controlled trials (RCTs) have shown that postoperative radiotherapy (RT) improves outcomes for operable individuals. Adding radiation to chemotherapy also improves outcomes for those with inoperable lung tumors that have not metastasized beyond regional lymph nodes.

Radiotherapy Techniques

Radiation therapy may be administered externally (i.e., a beam of radiation is directed into the body) or internally (i.e., a radioactive source is placed inside the body, near a tumor). External radiotherapy (RT) techniques include 'conventional' or 2-dimensional (2D) RT, 3-dimensional (3D) conformal RT, and intensity-modulated radiation therapy (IMRT).

Conventional External-Beam Radiotherapy

Methods to plan and deliver RT have evolved that permit more precise targeting of tumors with complex geometries. Conventional 2D treatment planning utilizes X-ray films to guide and position radiation beams. Bony landmarks bones visualized on X-ray are used to locate a tumor and direct the radiation beams. The radiation is typically of uniform intensity.

Three-Dimensional Conformal Radiotherapy

Radiation treatment planning has evolved to use 3D images, usually from computed tomography (CT) scans, to more precisely delineate the boundaries of the tumor and to discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Three-dimensional conformal RT (3D-CRT) involves initially scanning the individual in the position that will be used for the radiation treatment. The tumor target and surrounding normal organs are then outlined in 3D on the scan. Computer software assists in determining the orientation of radiation beams and the amount of radiation the tumor and normal tissues receive to ensure

coverage of the entire tumor in order to minimize radiation exposure for at risk normal tissue and nearby organs. Other imaging techniques and devices such as multi leaf collimators (MLCs) may be used to 'shape' the radiation beams. Methods have also been developed to position the individual and the radiation portal reproducibly for each fraction and to immobilize the individual, thus maintaining consistent beam axes across treatment sessions.

Intensity-Modulated Radiotherapy

Intensity-modulated radiotherapy is the more recent development in external radiation. Treatment planning and delivery are more complex, time-consuming, and labor-intensive for IMRT than for 3D-CRT. Similar to 3D-CRT, the tumor and surrounding normal organs are outlined in 3D by a scan and multiple radiation beams are positioned around the individual for radiation delivery. In IMRT, radiation beams are divided into a grid-like pattern, separating a single beam into many smaller 'beamlets'. Specialized computer software allows for 'inverse' treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target's prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor, surrounding tissues, and organs at risk, computer software optimizes the location, shape, and intensities of the beam ports to achieve the treatment plan's goals.

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and is proposed to improve local tumor control, with decreased exposure to surrounding, normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding under dosing within the tumor and may decrease toxicity by avoiding overdosing.

In addition to the clinical situations identified below, benefits may be allowed for indications and criteria recognized in the National Comprehensive Cancer Network Guidelines (NCCN Guidelines) that is supported by NCCN 1 or 2A recommended use.

Policy Application

All claims submitted under this policy's section will be processed according to the policy effective date and associated revision effective dates in effect on the date of service.

Diagnosis Codes

Not applicable

CURRENT CODING

CPT:

77301	NTSTY MODUL RADTHX PLN DOSE-VOL HISTOS	Commercial
77338	MLC IMRT DESIGN & CONSTRUCTION PER IMRT PLAN	Commercial

77385	INTENSITY MODULATED RADIATION TX DLVR SIMPLE	Commercial
77386	INTENSITY MODULATED RADIATION TX DLVR COMPLEX	Commercial
77301	NTSTY MODUL RADTHX PLN DOSE-VOL HISTOS	Medicaid Expansion
77338	MLC IMRT DESIGN & CONSTRUCTION PER IMRT PLAN	Medicaid Expansion
77385	INTENSITY MODULATED RADIATION TX DLVR SIMPLE	Medicaid Expansion
77386	INTENSITY MODULATED RADIATION TX DLVR COMPLEX	Medicaid Expansion

HCPCS:

G6015	Radiation tx delivery imrt	Commercial
G6016	Delivery comp imrt	Commercial
G6015	Radiation tx delivery imrt	Medicaid Expansion
G6016	Delivery comp imrt	Medicaid Expansion

References

- 1. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. Mar 2007; 82(3): 254-64. PMID 17224195
- 2. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. May 01 2008; 26(13): 2085-92. PMID 18285602
- 3. Shinohara E, Whaley JT. Radiation therapy: which type is right for me? Last reviewed: March 16, 2022. https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me. Accessed May 20, 2022.
- 4. Jagsi R, Griffith KA, Moran JM, et al. A Randomized Comparison of Radiation Therapy Techniques in the Management of Node-Positive Breast Cancer: Primary Outcomes Analysis. Int J Radiat Oncol Biol Phys. Aug 01 2018; 101(5): 1149-1158. PMID 30012527
- 5. Kaza E, Dunlop A, Panek R, et al. Lung volume reproducibility under ABC control and self-sustained breath-holding. J Appl Clin Med Phys. Mar 2017; 18(2): 154-162. PMID 28300372
- 6. Coon AB, Dickler A, Kirk MC, et al. Tomotherapy and multifield intensity- modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. Int J Radiat Oncol Biol Phys. Sep 01 2010; 78(1): 104-10. PMID 20004529
- 7. Dayes I, Rumble RB, Bowen J, et al. Intensity-modulated radiotherapy in the treatment of breast cancer. Clin Oncol (R Coll Radiol). Sep 2012; 24(7): 488- 98. PMID 22748561
- 8. Pignol JP, Truong P, Rakovitch E, et al. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. Radiother Oncol. Dec 2016; 121(3): 414-419. PMID

27637858

- 9. Barnett GC, Wilkinson J, Moody AM, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol. Jul 2009; 92(1): 34-41. PMID 19375808
- 10. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys. Feb 01 2012; 82(2): 715-23. PMID 21345620
- 11. Choi KH, Ahn SJ, Jeong JU, et al. Postoperative radiotherapy with intensity- modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03. Radiother Oncol. Jan 2021; 154: 179-186. PMID 32980384
- 12. Horner-Rieber J, Forster T, Hommertgen A, et al. Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). Int J Radiat Oncol Biol Phys. Apr 01 2021; 109(5): 1311-1324. PMID 33321192
- 13. Krug D, Koder C, Hafner MF, et al. Acute toxicity of normofractionated intensity modulated radiotherapy with simultaneous integrated boost compared to three-dimensional conformal radiotherapy with sequential boost in the adjuvant treatment of breast cancer. Radiat Oncol. Oct 13 2020; 15(1): 235. PMID 33050920
- 14. Forster T, Hommertgen A, Hafner MF, et al. Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2- year results of the multicenter randomized IMRT-MC2 trial. Radiother Oncol. Oct 2021; 163: 165-176. PMID 34480960
- 15. Hardee ME, Raza S, Becker SJ, et al. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. Int J Radiat Oncol Biol Phys. Mar 01 2012; 82(3): e415-23. PMID 22019349
- 16. Guttmann DM, Gabriel P, Kennedy C, et al. Comparison of acute toxicities between contemporary forward-planned 3D conformal radiotherapy and inverse-planned intensity-modulated radiotherapy for whole breast radiation. Breast J. Mar 2018; 24(2): 128-132. PMID 28703444
- 17. Rudat V, Alaradi AA, Mohamed A, et al. Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison. Radiat Oncol. Mar 21 2011; 6: 26. PMID 21418616
- 18. Rastogi K, Sharma S, Gupta S, et al. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. Radiat Oncol J. Mar 2018; 36(1): 71-78. PMID 29621872
- 19. Ho AY, Ballangrud A, Li G, et al. Long-Term Pulmonary Outcomes of a Feasibility Study of Inverse-Planned, Multibeam Intensity Modulated Radiation Therapy in Node-Positive Breast Cancer Patients Receiving Regional Nodal Irradiation. Int J Radiat Oncol Biol Phys. Apr 01 2019; 103(5): 1100-1108. PMID 30508620
- 20. Kivanc H, Gultekin M, Gurkaynak M, et al. Dosimetric comparison of three- dimensional conformal radiotherapy and intensity-modulated radiotherapy for left-sided chest wall and lymphatic irradiation. J Appl Clin Med Phys. Dec 2019; 20(12): 36-44. PMID 31680445
- 21. Zhao Y, Zhu J, Zhang X, et al. Integrated IMRT vs segmented 3D-CRT of the chest wall and supraclavicular region for Breast Cancer after modified Radical Mastectomy: An 8-year follow-up. J Cancer. 2021; 12(5): 1548-1554. PMID 33532000
- 22. Bezjak A, Rumble RB, Rodrigues G, et al. Intensity-modulated radiotherapy in the treatment of lung cancer. Clin Oncol (R Coll Radiol). Sep 2012; 24(7): 508- 20. PMID 22726417
- 23. Liao ZX, Komaki RR, Thames HD, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. Mar 01 2010; 76(3): 775-81. PMID 19515503
- 24. Louie AV, Granton PV, Fairchild A, et al. Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial. JAMA Oncol.

- Apr 01 2022; 8(4): 1-7. PMID 35201290
- 25. Shirvani SM, Juloori A, Allen PK, et al. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. Sep 01 2013; 87(1): 139-47. PMID 23920393
- 26. Harris JP, Murphy JD, Hanlon AL, et al. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. Mar 15 2014; 88(4): 872-84. PMID 24495591
- 27. Ling DC, Hess CB, Chen AM, et al. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. Jan 2016; 17(1): 18-23. PMID 26303127
- 28. Chun SG, Hu C, Choy H, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. Jan 2017; 35(1): 56-62. PMID 28034064
- 29. Koshy M, Malik R, Spiotto M, et al. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer. Jun 2017; 108: 222-227. PMID 28625640
- 30. Appel S, Bar J, Ben-Nun A, et al. Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes. Br J Radiol. May 2019; 92(1097): 20180960. PMID 30864828
- 31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer, Version 3.2022. Updated May 7, 2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 20, 2022.
- 32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer, Version 3.2022. Updated March 16, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 18, 2022.
- 33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small Cell Lung Cancer, Version 2.2022. Updated November 24, 2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed May 19, 2022.
- 34. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. May 2018; 8(3): 145-152. PMID 29545124
- 35. Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Pract Radiat Oncol. Jul 2018; 8(4): 245-250. PMID 29625898
- 36. Simone CB, Bogart JA, Cabrera AR, et al. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. May 2020; 10(3): 158-173. PMID 32222430
- 37. Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Pract Radiat Oncol. Nov 2016; 6(6): e219-e234. PMID 27659727

ND Committee Review

Internal Medical Policy Committee 11-19-2020 New Policy *Effective January 4, 2021*

Internal Medical Policy Committee 11-23-2021 Annual Review, No changes in criteria *Effective January 3, 2022*

Internal Medical Policy Committee 11-29-2022 Revision - Effective January 02, 2023

- *Updated* Coding
- *Updated* language with minor refinements

• Added Summary of Evidence

Internal Medical Policy Committee 7-26-2023 Revision with coding update - Effective June 19, 2023

- o *Removed* diagnosis codes
- o *Updated* with clarifying language

Internal Medical Policy Committee 7-16-2024 Annual Review Effective September 2, 2024

• Added Policy Application

Disclaimer

Current medical policy is to be used in determining a Member's contract benefits on the date that services are rendered. Contract language, including definitions and specific inclusions/exclusions, as well as state and federal law, must be considered in determining eligibility for coverage. Members must consult their applicable benefit plans or contact a Member Services representative for specific coverage information. Likewise, medical policy, which addresses the issue(s) in any specific case, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and the Company reserves the right to review and update medical policy periodically.